Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
paclitaxel polymer micelles + gemcitabine + lenvatinib
- Development stage
- Unknown
- Lead developer
- Shanghai Sixth People’s Hospital
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous, Oral
01
Overview
This combination therapy regimen consists of a novel nanoparticle formulation of paclitaxel (polymer micelles), the antimetabolite gemcitabine, and the multi-kinase inhibitor lenvatinib. It is being investigated by Shanghai 6th People's Hospital in the Phase 2 MAGNATE-S trial for the treatment of advanced, unresectable, or metastatic bone sarcomas that have progressed after first-line therapy. Paclitaxel polymer micelles are designed to improve solubility and reduce hypersensitivity reactions compared to traditional paclitaxel. Gemcitabine inhibits DNA synthesis by acting as a nucleoside analog, while lenvatinib targets multiple tyrosine kinases including VEGFR1-3, FGFR1-4, PDGFRα, KIT, and RET to inhibit angiogenesis and tumor cell proliferation. In the MAGNATE-S study, this specific combination is primarily allocated to patients with bone sarcoma, while a similar regimen substituting lenvatinib with anlotinib is used for soft tissue sarcoma.
- Other names
- Paclitaxel Micelles + Gemcitabine + Lenvatinib
02
Targets
DNA replication machinery / nascent DNAFGFR1 (Fibroblast growth factor receptor 1)FGFR2 (Keratinocyte growth factor receptor)FGFR3 (Fibroblast growth factor receptor 3)FGFR4 (Fibroblast growth factor receptor 4)KIT (c-KIT proto-oncogene receptor tyrosine kinase)PDGFRA (Platelet-derived growth factor receptor alpha)RET (Rearranged during transfection receptor tyrosine kinase)RNR (Ribonucleotide reductase)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR2 (Vascular endothelial growth factor receptor 2)VEGFR4 (Vascular endothelial growth factor Receptor-3)DNATUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on paclitaxel polymer micelles + gemcitabine + lenvatinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on paclitaxel polymer micelles + gemcitabine + lenvatinib.